Koneksa launches academic collaboration for Parkinson’s research

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Koneska Parkinson's disease Research

Digital biomarker company Koneksa has launched the first collaboration in the Koneska Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its Neuroscience Toolkit into research programs.

The partnership, alongside Oregon Health & Science University (OHSU), will enable the inclusion of app-and actigraphy-based digital measures and electronic patient reported outcome (ePRO) instruments from Koneksa’s Neuroscience Toolkit into a study comparing short-acting versus long-acting levodopa in Parkinson’s disease.

Koneksa’s Neuroscience Toolkit implements a variety of digital assessments that can be combined to collect data for measures of interest.

The OHSU team, led by Dr. Delaram Safarpour, is investigating changes in the neurophysiological correlates of PD with carbidopa-levodopa immediate release compared to long-acting levodopa (Rytary), as well as changes in gait performance at intervals of 30 minutes for a total of 4 hours during each visit.

According to Koneska, this research will provide strong support for clinical profiles of short-versus-long acting levodopa in PD corresponding to objective physiological measures.

Martina Mancini, associate professor of neurology, OHSU School of Medicine and co-investigator of the study, said: “We are collaborating with Koneksa to enhance our study’s objectives. We’ll be including smartphone- and actigraphy-based digital measures and electronic patient reported outcome (ePRO) instruments into our study. Our lab uses new technologies to better understand and measure motor impairments, with the goal of learning how to better help patients with these conditions."

“Novel, objective metrics, like those made possible with Koneksa’s technology and toolkit, allow us to expand upon what we’ve been able to do in the clinic. In particular, digital at-home measures of daily physical activity, gait and mobility, motor functionality, sleep, and ePRO measures of quality of life all have the potential to uniquely complement OHSU’s in-clinic assessments, offering new and real-world-setting patient insights to support the study’s objectives.”

John Wagner, chief medical officer at Koneksa, added: “Koneksa is proud to extend our contribution to critical neuroscience research through KAPP-PD, and we’re delighted to get the program underway with our first collaboration.”

“These measures will support OHSU in both in-clinic and at-home patient monitoring of critical parameters of interest for this study. We’re committed to helping to get new and better treatments to patients faster, and that’s a vision that OHSU’s Balance Disorders Laboratory shares.”

Related topics Bio Developments Biopharma Culture

Related news

Show more

Follow us